tipranavir: Clinical Trials

54 trials of tipranavir, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

44 completed, 6 terminated, 3 approved for marketing, 1 withdrawn. 27 Phase 1, 10 Phase 2, 10 Phase 3, 2 Phase 4, 1 Not applicable.

By phase and status

Phase	Trials	Status
Phase 1	27	Completed 25, Terminated 2
Phase 2	10	Completed 8, Terminated 2
Phase 3	10	Completed 7, Terminated 3
Phase 4	2	Completed 2
Not applicable	1	Completed 1

Follow tipranavir: new trials by email Literature Review of tipranavir trials Research Report on tipranavir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy triple therapy, dual therapy - HIV	Phase 3	Completed	University Hospital, Tours	224	2014-12-01	2025-12-26
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice. Tipranavir, ritonavir - HIV Infections		Completed	Boehringer Ingelheim	42	2009-09-01	2014-03-20
Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort Tipranavir - HIV Infections		Withdrawn	Boehringer Ingelheim		2008-06-01	2018-08-31
Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers Tipranavir, Ritonavir - Healthy	Phase 1	Completed	Boehringer Ingelheim	32	2008-04-01	2014-09-19
Optimizing Treatment for Treatment-Experienced, HIV-Infected People Enfuvirtide, Raltegravir, Darunavir - HIV Infections	Phase 3	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	517	2008-01-01	2021-11-04
Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours tipranavir/ritonavir (dose reduction) - HIV Infections	Phase 4	Completed	Germans Trias i Pujol Hospital	11	2007-12-01	2019-12-05
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients tipranavir, ritonavir - HIV Infections	Phase 2	Completed	Boehringer Ingelheim	85	2007-10-01	2014-06-06
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI Tipranavir, Darunavir, Ritonavir - HIV Infections	Phase 3	Terminated	Boehringer Ingelheim	40	2007-09-01	2014-05-14
Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects Tipranavir, Ritonavir, Darunavir - Healthy	Phase 1	Completed	Boehringer Ingelheim	52	2007-08-01	2014-09-29
Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy tipranavir - HIV Infections		Completed	Boehringer Ingelheim	42	2007-06-01	2014-08-08
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation tipranavir, ritonavir - HIV Infections	Phase 3	Terminated	Boehringer Ingelheim	11	2007-03-01	2014-05-14
Clinical Trial of CNS-targeted HAART (CIT2) FDA Approved Antiretroviral Therapy (see list below) - HIV Infections	Phase 2 / Phase 3	Completed	University of California, San Diego	59	2007-03-01	2014-04-23
Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects Tipranavir/Ritonavir, Rosuvastatin - HIV Infections	Phase 1	Completed	Johns Hopkins University	29	2007-02-01	2016-02-04
Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers Tipranavir, Ritonavir, Valaciclovir - Healthy	Phase 1	Completed	Boehringer Ingelheim	29	2007-02-01	2014-08-27
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC tipranavir, ritonavir, Optimized Background Regimen (OBR) - HIV Infections	Phase 3	Terminated	Boehringer Ingelheim	33	2007-02-01	2014-06-27
Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients. Tipranavir, Ritonavir - HIV Infections		Completed	Boehringer Ingelheim	65	2006-08-01	2014-04-07
Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV Tipranavir capsules, Ritonavir capsules - HIV Infections	Phase 1 / Phase 2	Terminated	Boehringer Ingelheim	3	2006-08-01	2014-09-01
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir Buprenorphine, Tipranavir and ritonavir - HIV Infections	Not applicable	Completed	Yale University	12	2006-05-01	2020-04-20
Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers Tipranavir, Ritonavir, Efavirenz - Healthy	Phase 1	Completed	Boehringer Ingelheim	34	2006-04-01	2014-08-27
Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers Tipranavir capsule, Tipranavir solution, Ritonavir capsule - Healthy	Phase 1	Completed	Boehringer Ingelheim	34	2006-01-01	2014-09-18

Showing 20 of 54. Sign in to see all of them.

Conditions studied

HIV Infections (30) · Hepatic Insufficiency (2) · AIDS Dementia Complex (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · HIV-Associated Lipodystrophy Syndrome (1) · Lipodystrophy (1)

Countries

United States (14) · Germany (10) · Italy (10) · Spain (10) · France (9) · Canada (7) · Australia (6) · Belgium (6) · Brazil (6) · Greece (6) · Portugal (6) · Argentina (5) · Denmark (5) · United Kingdom (5) · Netherlands (4)

Top investigators

Andrew D Carr, MD (1) · Bonaventura Clotet, MD, PhD (1) · David A Cooper, MD (1) · Karen T. Tashima, MD (1)

Results publications

PMID 16890833, PMID 16470119, PMID 16988514, PMID 18366444, PMID 18795962, PMID 18989231, PMID 19726139, PMID 20002783, PMID 20003457, PMID 20632458, PMID 21283017, PMID 22007990, PMID 22083071, PMID 22129166, PMID 23305215, PMID 23392467, PMID 23494984, PMID 24352352, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25950206, PMID 25959631, PMID 26202768, PMID 26595748, PMID 26918544, PMID 27540363, PMID 29369162, PMID 29520730, PMID 29528944, PMID 30134297, PMID 30358179, PMID 30530925, PMID 30715324, PMID 31135883, PMID 31350995, PMID 31489678, PMID 32015036, PMID 32451908, PMID 33252495, PMID 33318014, PMID 34076612, PMID 34732682, PMID 40741959, PMID 42828638

NIH funding

2004 (1), R01HL065953 (1), R01MH058076 (1)